ABOUT COHERUS

SCIENTIFIC ADVISTORY BOARD

SCIENTISTS AT LEADING RESEARCH INSTITUTIONS AND INDEPENDENT CONSULTANTS MAKE UP OUR SCIENTIFIC ADVISORY BOARD, PROVIDING EXTERNAL PERSPECTIVE AND A FORUM FOR DISCUSSIONS ON PRODUCT DEVELOPMENT, MANUFACTURING PROCESSES, MARKET TRENDS AND MORE.

  • V. BRYAN LAWLIS, PH.D.

    CHAIRMAN, INDEPENDENT CONSULTANT

    • V. BRYAN
      LAWLIS, PH.D.

      CHAIRMAN, INDEPENDENT CONSULTANT

      FORMERLY

      Genentech

      V. Bryan Lawlis, Ph.D. has served on our Board of Directors since May 2014 and prior to that he served as the chairman of our Scientic Advisory Board from November 2012, until he joined the board in May 2014.

      Since August 2011, he has served as the President and Chief Executive Officer of ltero Biopharmaceuticals, LLC, a privately held limited liability holding company, which has held the assets of ltero Biopharmaceuticals, Inc., or Itero Biopharmaceuticals, since August 2011. Dr. Lawlis co-founded and served as President and Chief Executive Officer of Itero Biopharmaceuticals, from 2006, until it discontinued operations in August 2011. Prior to that, he served as President and Chief Executive Officer of Aradigm Corporation, a pharmaceutical company, from August 2004, and served on its board of directors from February 2005, continuing in both capacities until August 2006. Dr. Lawlis served as Aradigm Corporation’s President from June 2003 to August 2004, and as its Chief Operating Officer from November 2001 to June 2003. Previously, Dr. Lawlis co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical manufacturing company, served as its President and Chief Executive Officer from 1996 to 1999, and as Chairman from 1999 to 2001, when it was sold to Diosyth RTP, Inc., a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., a biotechnology company, and Genentech. His last position at Genentech was Vice President of Process Sciences. Dr. Lawlis has served on the boards of directors of two privately held companies, Sutro Biopharmaceuticals, Inc. since 2003 and Reform Biologics, LL since February 2014. He has also served on the boards of directors at BioMarin Pharmaceutical Inc., a public biopharmaceutical company since June 2007, and Geron Corporation, a public biopharmaceutical company, since March 2012.

      Dr. Lawlis holds a B.A. in Microbiology from the University of Texas at Austin, and a Ph.D. in Biochemistry from Washington State University.

      We believe Dr. Lawlis is qualified to serve on our Board of Directors due to his longtime involvement in the biotechnology industry, and extensive service as a director or officer of other life sciences companies.

  • WILLIAM F. BENNETT, PH.D.

    PRINCIPAL, BIOSCOPE ASSOCIATES

    • WILLIAM F.
      BENNETT, PH.D.

      PRINCIPAL, BIOSCOPE ASSOCIATES

      FORMERLY

      Genentech

      William F. Bennett, Ph.D. is a Principal of Bioscope Associates LLC.

      Until 2009, he was Sr. Director of Regulatory Policy at Genentech and led the Genentech Biosimilars working group. He was at Genentech for 18 years altogether, having held high-level positions in Research, Bioprocess Development and Regulatory Affairs. He helped guide Genentech over many years through his participation on the Research Review, Product Development, Process Development Review and Appointments and Promotions Committees. During a period away from Genentech, as CSO at Sensus Corporation, he led the research and development of Somavert (a treatment for acromegaly) and was the Vice President of Research at Cor Therapeutics as well as Senior Vice President of R&D at Hyseq/Nuvelo. Dr. Bennett returned to Genentech in 2003.

      Dr. Bennett has a B.A. in Chemistry from TCU and a Ph.D. in Biochemistry from the University of Texas Southwestern Medical School. He was named a Distinguished Alumnus of TCU in 2010 and serves on the TCU Science & Engineering Advisory Board.

  • JOHN F. CARPENTER, PH.D.

    UNIVERSITY OF COLORADO SCHOOL OF PHARMACY

    • JOHN F.
      CARPENTER, PH.D.

      UNIVERSITY OF COLORADO SCHOOL OF PHARMACY

      John F. Carpenter, Ph.D. is Professor of Pharmaceutical Sciences at the University of Colorado School of Pharmacy, and a Co-Founder and Co-Director of the University of Colorado Center for Pharmaceutical Biotechnology.

      Dr. Carpenter has published more than 230 peer-reviewed papers and is an inventor on 30 issued patents. He is Editor for Reviews and Commentaries for Journal of Pharmaceutical Sciences. He serves on the Editorial Advisory Boards for Pharmaceutical Research, The AAPS Journal, Journal of Pharmaceutical Sciences, Current Pharmaceutical Biotechnology, Molecular Pharmaceutics and BioPharm International. He has received several teaching awards and The Ebert Prize. He is a Fellow of the American Association for Advancement of Science and the American Association of Pharmaceutical Scientists (AAPS) and has received the AAPS Research Achievement Award in Biotechnology. He also is the Organizer for the Colorado Protein Stability Conferences.

      He obtained his B.S. in Zoology from Duke University and his M.S. in Zoology from Oregon State University. He received his PhD. In Biology from the University of Southwest Louisiana.

  • ANDREW J.S. JONES, D. Phil.

    INDEPENDENT CONSULTANT

    • ANDREW J.S.
      JONES, D. Phil.

      INDEPENDENT CONSULTANT

      FORMERLY

      Genentech

      Andrew J.S. Jones, D. Phil, spent 23 years from 1981 to 2004, at Genentech. Initially a scientist in the Protein Biochemistry Department, he was the founding Director of the Medical and Analytical Chemistry Department from 1983 to 1987. As staff scientist from 1988, he played various roles in the company including project team leader and also worked in the Pharmaceutical R&D Department from 1987 to 1994. Since 2004, Dr. Jones has worked as a consultant to various biopharmaceutical companies. He was the Head of the Scientific Advisory Board for Itero Biopharmaceuticals from 2009 to 2011.

      Dr. Jones obtained his B.A. (Honors) degree in Biochemistry from St. John's College, Oxford University. He received his D. Phil. degree in Biology from the University of York and performed postdoctoral research at McMaster University, under a Multiple Sclerosis Society of Canada Fellowship, and also at Cornell University.

  • JAMES MILLER, PH.D.

    INDEPENDENT CONSULTANT

    • JAMES
      MILLER, PH.D.

      INDEPENDENT CONSULTANT

      FORMERLY

      Amgen, Regeneron

      James A. Miller, Ph.D. is currently an independent consultant to the biopharmaceutical industry.

      Dr. Miller was recently Vice President of Process Development at Insmed, Inc., where he was involved with the sale of the company to Merck, Inc., with whom he continued to work as Senior Director of Process Development at the newly formed entity, Merck Boulder. From 2000 to 2003, Dr. Miller was Executive Vice President and co-founder of Saronyx, Inc., a company that developed web-enabled interfaces for data exchange between pharmaceutical development specialists and contract research organizations. From 1998 to 2000, he was Senior Director of Preclinical Development at Regeneron Pharmaceuticals, Inc., where he was responsible for the departments of pharmacology, pharmacokinetics, analytical assay and drug formulation/stability. From 1987 to 1998, Dr. Miller worked at Amgen in a number of roles, including founding the neurobiology department and undertaking leadership of the BDNF development team.

      Dr. Miller received his B.S. degree in Biology from the University of Oregon and a Ph.D. in Chemistry from the California Institute of Technology. He also received postdoctoral training in Physiology at the University of Colorado Medical School and the Yale University School of Medicine.

  • CARL WARE, PH.D.

    DIRECTOR, SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE

    • CARL
      WARE, PH.D.

      DIRECTOR, SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE

      Carl F. Ware, Ph.D. is a Director and Professor at the Infectious and Inflammatory Disease Center at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla California. He is a leading immunologist and virologist, internationally recognized for his scientific discoveries and advances in the study of the immune system, leading to new therapeutics for autoimmune and viral diseases and cancer.

      Dr. Ware received his doctorate in 1979 in Molecular Biology and Biochemistry at the University of California, Irvine, where he began his scientific research career by studying tumor destroying cytokines with Professor Gale A. Granger. Dr. Ware’s postdoctoral training included research with Dr. Jack Strominger and Dr. Tim Springer at the Dana-Farber Cancer Institute, Harvard Medical School. Dr. Ware established his own research laboratory in 1982 in the Biomedical Sciences Program at the University of California, Riverside, advancing to full professor in 1993. In 1996, he joined the La Jolla Institute for Allergy and Immunology as head of the Division of Molecular Immunology.

      In 2010, he was recruited to the Sanford Burnham Prebys Medical Discovery Institute as Center Director, and also holds a joint appointment in the Department of Biology at the University of California, San Diego.

leadership

view now

board of directors

view now